Have any questions? [email protected] +86-21-58998590
Structure search

CBP/p300-IN-23


CAS No. : 1020399-52-3

1020399-52-3
Price and Availability of CAS No. : 1020399-52-3
Size Price Stock
100 mg Get quote
250 mg Get quote
500 mg Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-114510
M.Wt: 623.92
Formula: C19H12Br4O4
Purity: >98 %
Solubility:
Introduction of 1020399-52-3 :

CBP/p300-IN-23 is a epigenetic multiple ligand. CBP/p300-IN-23 inhibits Aspergillus nidulans RmtA with an IC50 of 29 μM. CBP/p300-IN-23 inhibits human PRMT1, p300/CBP HAT, CARM1, SET7, SIRT1 and SIRT2. CBP/p300-IN-23 inhibits methylation of histone H3K4, H4R3, and H3R17 residues. CBP/p300-IN-23 induces apoptosis, arrests cell cycle in S phase, and triggers granulocytic differentiation in leukemia cells. CBP/p300-IN-23 can be used for the research of leukemia[1]. In Vitro:CBP/p300-IN-23 (Compound 4j) inhibits fungal RmtA with an IC50 of 29 μM[1].
CBP/p300-IN-23 (50 μM) inhibits human PRMT1 activity by 91.1% using histone H4 as substrate[1].
CBP/p300-IN-23 (100 μM; 90 min) strongly inhibits human CARM1 and SET7[1].
CBP/p300-IN-23 (50 μM; 24 h) reduces H3K4, H4R3, and H3R17 methylation in U937 cells[1].
CBP/p300-IN-23 (50 μM; 90 min) inhibits p300/CBP HAT activity by 61%[1].
CBP/p300-IN-23 (25 μM; 2 h) inhibits SIRT1 and SIRT2[1].
CBP/p300-IN-23 (25 μM; 30 h) induces 28% apoptosis in human leukemia U937 cells[1].
CBP/p300-IN-23 (0.5-5 μM; 30 h) induces dose-dependent granulocytic differentiation in human leukemia U937 cells, with 96.1% CD11c-positive cells at 5 μM after 30 h of treatment[1].
CBP/p300-IN-23 (25 μM; 30 h) induces S phase cell cycle arrest in human leukemia U937 cells[1].

Your information is safe with us.